🇺🇸

US SEC Filing Intelligence

· daily

DOE Energy & National Labs Contracts — March 07, 2026

DOE's NNSA awarded General Atomics a non-competitive $91.4M contract for inertial confinement fusion (ICF) targets R&D, part of a $547M ceiling through potential 2035, signaling robust revenue visibility and established dominance in high-priority national lab work. Cost-plus-fixed-fee structure lowers execution risk amid $43.6M already outlayed. Investors gain bullish exposure to sustained U.S. fusion energy R&D funding, with $456M in unobligated options as key upside.

1 total filings
· daily

DHS Homeland Security Contracts — March 07, 2026

DHS CBP awarded $6.15B in 10 firm fixed price contracts for Texas border barriers/walls, signaling massive infrastructure spend starting March 2026 with $0 outlays to date except one legacy deal. Barnard Construction dominates with 42% ($2.59B across 3 awards), followed by Spencer (15%, $954M across 3) and Fisher Sand (20%, $1.22B), offering high-confidence revenue visibility through 2028. All open-competition wins highlight sector resurgence, but execution risks loom from cost-plus exposure and remote TX sites.

10 total filings
· daily

VA Healthcare & Services Contracts — March 07, 2026

Optum Public Sector Solutions (UnitedHealth Group subsidiary) captured 100% of $1.14B in VA medical-managed healthcare delivery orders awarded in this period, underscoring UNH's dominance in government healthcare services (PSC Q201). Both 1-month contracts (Nov/Dec 2025 performance) carry bullish revenue potential but face execution hurdles from $0 outlayed and post-performance award dates. Concentration risk is high as all value flows to one entity in the health insurance sector (NAICS 524114).

2 total filings
· daily

Federal Construction & Infrastructure Contracts — March 07, 2026

DHS/CBP awarded $6.15B in 10 federal contracts on/near March 5-7, 2026, overwhelmingly for Texas border wall/barrier/waterborne construction (9/10 contracts, $5.93B total), signaling a major infrastructure push with zero outlays to date for future revenue. Barnard Construction dominates with 3 wins totaling $2.59B (42% of period value), followed by Spencer Construction ($954M across 3 contracts) and Fisher Sand ($1.22B). All firm-fixed-price structures expose winners to cost risks but provide high revenue visibility through 2027-2028.

10 total filings
· daily

Federal Professional Services Contracts — March 07, 2026

Three engineering services awards totaling $440M obligated (potentials exceeding $2.4B) underscore strong federal demand for NAICS 541330 providers, with USAID favoring small/disadvantaged firms via set-asides. Long-term 5-year contracts to 2028-2030 offer revenue visibility, though varying outlays ($192M total) signal execution pacing risks. Investors should prioritize govcon firms with small biz designations for USAID upside and large players like SAIC for GSA ceilings.

3 total filings
· daily

Significant Contract Modifications ($10M+) — March 07, 2026

This period reveals a $9B surge in significant contract modifications, with ~68% ($6.1B) concentrated in DHS/CBP border barrier/wall projects across Texas sectors, signaling renewed federal infrastructure momentum bullish for specialized construction firms. Healthcare services capture $1.7B (19%) via VA and HHS wins, bolstering UnitedHealth's Optum unit. Remaining $1.2B spans R&D/engineering in space, defense, and humanitarian aid, all under bullish signals with future revenue visibility despite execution risks.

19 total filings
· daily

Contract Option Exercises — March 07, 2026

DHS/CBP dominates with $7.8B+ in border barrier/wall contracts awarded to construction firms like Barnard ($2.6B), Fisher Sand ($1.2B), and Spencer ($954M), signaling massive future revenue from 2026 starts despite $0 outlays to date. UnitedHealth's Optum secures $1.1B in VA healthcare deals, bolstering managed care exposure. Broader themes include firm fixed-price risks in construction and high option upside in services/R&D contracts totaling ~$9B obligated.

19 total filings
· daily

All HHS Contracts — March 07, 2026

SERCO INC's $589M CMS delivery order for eligibility support services, with $442M already outlayed (75% execution), provides high-confidence revenue through June 2026 and potential to 2028 at up to $876M total. This single large HHS contract underscores concentrated spending on health IT infrastructure under NAICS 541512. Investors gain bullish exposure via SERCO but face execution risks from firm-fixed pricing and subawards.

1 total filings
· daily

All DOE Contracts — March 07, 2026

DOE's NNSA awarded General Atomics a $91.4M non-competitive contract for inertial confinement fusion (ICF) targets R&D, with base + options totaling $547.2M through potential 2035, signaling strong revenue visibility for this established player. Total outlays of $43.6M to date and $455.8M in unobligated options highlight front-loaded execution but substantial upside. Investors in nuclear R&D should note sustained federal commitment to experimental sciences amid options exercise risks.

1 total filings
· daily

Mega Contracts Monitor ($100M+) — March 07, 2026

A surge in mega contracts totaling $8.79B highlights a massive ramp-up in DHS/CBP border barrier construction, with 11 awards exceeding $6.5B concentrated in Texas sectors, signaling policy-driven infrastructure acceleration and bullish tailwinds for select contractors. Repeat wins by Barnard Construction ($2.59B across 3 contracts) and Spencer Construction ($954M across 3) underscore execution prowess amid full/open competition. Healthcare services see $1.72B in VA and HHS wins for UnitedHealth/Optum and Serco, while space/defense/USAID add diversified exposure; near-zero outlays ($1.25B total) flag delayed but high-visibility revenue.

17 total filings
· daily

High-Value Federal Grants ($5M+) — March 07, 2026

This period reveals a $9B surge in high-value federal contracts dominated by $6.3B in DHS/CBP border barrier/wall projects across Texas sectors, awarded to a concentrated group of constructors like Barnard ($2.6B across 3 wins) and Spencer ($0.95B across 3 wins). Healthcare services capture $1.7B, led by UnitedHealth's Optum ($1.14B in VA managed care), while R&D/engineering adds $1B with long-tail potential up to $5B+ via options. All 19 awards signal bullish future revenue, though $0 outlays on 14 contracts delay near-term cash flows amid firm-fixed-price execution risks.

19 total filings
· daily

DOE Energy Grants — March 07, 2026

DOE's NNSA non-competitively awarded General Atomics $91.4M for inertial confinement fusion (ICF) targets R&D, with base + options at $547.2M through 2029 and potential to 2035, signaling bullish revenue visibility via cost-plus-fixed-fee structure. $43.6M outlays to date and $1.8M subawards indicate front-loaded progress with low execution risk for this established non-small business. Key upside lies in $455.8M unobligated options amid NNSA's experimental sciences focus.

1 total filings
· daily

General Federal Contracts — March 07, 2026

A surge in DHS/CBP border barrier contracts totaling ~$5.9B across 10 awards signals strong future revenue for construction firms like Barnard (~$2.6B across 3 wins) and Spencer (~$1B across 4 wins), amid zero outlays indicating delayed but committed funding. Healthcare services see $1.1B+ in VA awards to Optum (UnitedHealth sub), while R&D contracts (NASA, DOE, GSA) add diversified upside via unexercised options exceeding $4B potential. All 19 bullish signals prioritize firm fixed price execution risks but highlight sector tailwinds in border security and federal healthcare.

19 total filings
· daily

All NASA Contracts — March 07, 2026

Astrobotic Technology Inc. secured a $314M NASA contract for VIPER rover delivery, with $276M already outlayed, signaling strong execution and committed revenue in space R&D. This full/open competition win by a small business underscores NASA's reliance on commercial providers for lunar missions. Investors should monitor completion risks through October 2026 for potential follow-on opportunities amid firm fixed price exposure.

1 total filings
· daily

Global High-Priority Regulatory Events — March 07, 2026

The 16 filings reveal a dominant theme of financial distress across small-cap Indian companies, with 8 explicit insolvency-related updates (Hindware Home Innovation, Ushdev International, DiGiSPICE Technologies, Reliance Home Finance, Radhagobind Commercial, Tijaria Polypipes, Baron Infotech, JCT Limited) signaling widespread CIRP, liquidation, and creditor meetings amid no disclosed YoY/QoQ financial trends. Neutral-to-negative sentiment prevails (10/16 negative or neutral), with high materiality (avg 7.8/10) driven by NCLT proceedings, contrasting sparse positive regulatory resolutions like MRPL's rumor denial and Rathi's legal clearance. No period-over-period financial comparisons, insider trades (except promoter encumbrance), or capital allocation details are provided, limiting quantitative trends, but forward-looking catalysts cluster around March 2026 (voting results by Mar14, open offer Mar17-Apr2, CoC Mar9, NCLT Mar13). Portfolio-level pattern: Insolvency cluster in manufacturing/niche sectors (pipes, steel, fintech) suggests sector contagion risk, while open offers and mergers offer M&A alpha. Overall, bearish for exposed longs, opportunistic for distress plays.

16 high priority 16 total filings
· daily

Biotech Small-Cap Approvals — March 06, 2026

Four neutral ANDA approvals for generic drugs were granted to small-cap pharma firms (Zydus Pharms, Glenmark Speclt, Epic Pharma LLC, Macleods Pharms Ltd) in early March 2026, signaling standard portfolio expansions without special designations or therapeutic details. This cluster reflects steady FDA throughput for generics but lacks premium positioning or market visibility, muting investment impact. Institutional investors should monitor for launch execution amid pricing risks, viewing this as low-materiality noise in biotech small-caps.

4 total filings
· daily

New Drug Approvals (Original) — March 06, 2026

FDA approved 4 generic ANDAs (all original approvals under standard review) from March 2-4, 2026, enabling portfolio expansions for Zydus Pharms, Glenmark Speclt, Epic Pharma LLC, and Macleods Pharms Ltd. These neutral signals offer incremental revenue potential for generic sponsors amid pricing pressures and unspecified indications/therapeutic areas. No innovative NMEs or special designations limit blockbuster impact, signaling steady but low-materiality generic erosion vs. branded pharma.

4 total filings